Sign up today to receive exclusive access to personalized
guidance, practical tools, and expert-driven insights to help
accelerate cardiac PET adoption for your site.

This new series features April Mann, a specialist with 25 years of experience in cardiac PET, as she shares her perspective on the clinical and operational advantages of Flyrcado. Each episode offers actionable advice and expert analysis to help you enhance diagnostic confidence and optimize patient care.

What else can I expect from Flyrcado Forward?

PET = Position emission tomography, MPI = Myocardial perfusion imaging

Interested in more information? Request sales contact.

For more information about Flyrcado, and to view full Prescribing Information, please visit our website.

Flyrcado Support Resources

• Flyrcado Support Line: 800 729 0701

• Medical Affairs: 800 654 0118
  (option 2, then option 3) or [email protected]

• Pharmacovigilance: 800 654 0118
  (option 2, then option 1) or [email protected]

• Clinical Applications: [email protected]

• Customer Service: 800 292 8514

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

• Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. 
• Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

• Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information for additional important safety information.